- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07718425
EndoBreast Study - Assessment of Feasibility, Functional Outcomes, and Sensitivity of the Areola-Nipple Complex in Endoscopic Mastectomy (EndoBreast)
Study Design Prospective, single-center, observational, non-interventional study conducted in routine clinical practice. No investigational treatments or modifications to standard diagnostic, therapeutic, or follow-up procedures are planned. Consecutive eligible patients undergoing endoscopic nipple-sparing mastectomy (NSM) with immediate breast reconstruction will be prospectively enrolled.
Background and Rationale Nipple-sparing mastectomy with immediate reconstruction is an established treatment for selected patients with breast cancer and women undergoing prophylactic mastectomy because of hereditary risk. Preservation of the nipple-areola complex (NAC) improves cosmetic outcomes, body image, and patient satisfaction while maintaining oncological safety. Endoscopic NSM is a minimally invasive alternative that may reduce scarring, surgical trauma, and recovery time while improving aesthetic outcomes without compromising oncological radicality. However, evidence remains limited, particularly in Europe, regarding feasibility, perioperative safety, sensory recovery, quality of life, reconstructive outcomes, and long-term oncological results. This study aims to prospectively collect real-world data from a consecutive cohort treated at a specialized breast center.
Primary Objective To evaluate the feasibility and surgical safety of endoscopic NSM with immediate breast reconstruction in patients undergoing prophylactic or therapeutic mastectomy.
Secondary Objectives To evaluate NAC sensory recovery at 6 and 12 months; assess oncological safety through surgical radicality and follow-up; evaluate quality of life and patient satisfaction using validated questionnaires; describe disease-free survival (DFS), overall survival (OS), reconstructive and aesthetic outcomes; and assess postoperative hospital stay.
Primary Endpoints Overall incidence of early surgical complications; incidence of NAC necrosis, skin flap necrosis, infection, seroma, hematoma, hospital readmission, reoperation, and implant loss; recovery of NAC sensation at 6 and 12 months; and pathological assessment of retroareolar margin status.
Secondary Endpoints BREAST-Q scores; local, regional, and distant recurrence; DFS; OS; and reconstructive/aesthetic outcomes.
Study Population and Sample Size Thirty consecutive adult women undergoing prophylactic or therapeutic NSM with immediate implant-based reconstruction according to multidisciplinary evaluation.
Main Inclusion Criteria Female; age 18-75 years; indication for prophylactic or therapeutic NSM; breast volume suitable for endoscopic surgery; Regnault ptosis ≤ Grade II; eligibility for immediate implant-based reconstruction; WHO/ECOG performance status <3; written informed consent.
Main Exclusion Criteria Inflammatory breast cancer or skin involvement; previous breast cancer surgery or radiotherapy to the affected breast; BMI >35 kg/m²; active smoking; ASA Physical Status >2; pregnancy or breastfeeding; inability to provide informed consent; participation in incompatible interventional clinical trials.
Observed Procedure Endoscopic NSM through a lateral inframammary incision using a combined open/endoscopic dissection. Intraoperative retroareolar frozen section and axillary staging (sentinel lymph node biopsy or axillary dissection) will be performed when indicated. Immediate prepectoral implant-based reconstruction will follow.
Data Collection and Follow-up Clinical, surgical, pathological, perioperative, and follow-up data will be prospectively recorded in a dedicated electronic Case Report Form. Patient-reported outcomes will be assessed using the validated BREAST-Q Reconstruction Module. Assessments will be performed preoperatively, intraoperatively, at 30 and 60 days, 6 months, 12 months, and annually up to 5 years. BREAST-Q will be administered at 6 months, 12 months, and annually thereafter.
Study Duration Enrollment will continue until 30 patients have been recruited. Each participant will be followed for 5 years.
Statistical Analysis This descriptive exploratory study will summarize categorical variables as frequencies and percentages and continuous variables using appropriate descriptive statistics. Long-term oncological outcomes will be reported as observed events, with DFS and OS estimated using Kaplan-Meier analysis when appropriate.
Ethics The study is observational and does not alter routine clinical management. No additional significant risks beyond standard surgical care are anticipated. Written informed consent is mandatory. Personal data will be pseudonymized and processed in accordance with the General Data Protection Regulation (EU 2016/679) and applicable national legislation.
Expected Benefits and Risks The study will provide prospective evidence on the feasibility, safety, functional recovery, quality of life, reconstructive outcomes, and oncological effectiveness of endoscopic NSM.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Contato de estudo
- Nome: Massimiliano Bortolini, MD
- Número de telefone: 003901515156616
- E-mail: massimiliano.bortolini@aslbi.piemonte.it
Locais de estudo
-
-
BI
-
Ponderano, BI, Itália, 13875
- Recrutamento
- Ospedale degli Infermi ASL BI
-
Contato:
- Massimiliano Bortolini, MD
- Número de telefone: 003901515156616
- E-mail: massimiliano.bortolini@aslbi.piemonte.it
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Método de amostragem
População do estudo
Descrição
Inclusion Criteria:
- Female; age 18-75 years;
- indication for prophylactic or therapeutic NSM;
- breast volume suitable for endoscopic surgery;
- Regnault ptosis ≤ Grade II;
- eligibility for immediate implant-based reconstruction;
- WHO/ECOG performance status <3;
- written informed consent.
Exclusion Criteria:
- Inflammatory breast cancer or skin involvement;
- previous breast cancer surgery or radiotherapy to the affected breast;
- BMI >35 kg/m²; active smoking; ASA Physical Status >2;
- pregnancy or breastfeeding;
- inability to provide informed consent;
- participation in incompatible interventional clinical trials.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
Coortes e Intervenções
Grupo / Coorte |
Intervenção / Tratamento |
|---|---|
|
Breast cancer patients
breast cancer patients recruited for endoscopic mastectomy
|
Endoscopic NSM through a lateral inframammary incision using a combined open/endoscopic dissection.
Intraoperative retroareolar frozen section and axillary staging (sentinel lymph node biopsy or axillary dissection) will be performed when indicated.
Immediate prepectoral implant-based reconstruction will follow.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Overall incidence of early surgical complications
Prazo: adverse events in the first 90 days
|
incidence of NAC necrosis, skin flap necrosis, infection, seroma, hematoma, hospital readmission, reoperation, and implant loss
|
adverse events in the first 90 days
|
|
recovery of NAC sensation
Prazo: 6-12 months
|
NAC sensitivity is assessed at five anatomical points: the four quadrants of the areola and the nipple tip. Two complementary tests are used:
|
6-12 months
|
|
pathological assessment of retroareolar margin status
Prazo: 1 month
|
For histological examination of the retroareolar tissue (intraoperative and/or final), the disc-shaped tissue fragment must be submitted with the surface facing the nipple (the "true margin") marked with a suture tag or a metal clip. Examination of the retroareolar parenchyma may be performed during surgery as an intraoperative frozen-section examination, or after surgery as a final examination. The retroareolar fragment, generally single, is measured (maximum diameter and thickness), and the surface facing the nipple must be marked by the pathologist with India ink. Both the frozen-section and the final histopathological examination are performed using serial sections approximately 5 mm apart, from the nipple-facing surface to the breast-facing surface, on the entire submitted specimen. For the intraoperative histological examination, an average of 3 frozen-tissue sections are prepared at 200-300 micron intervals, followed by an additi |
1 month
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Sobrevida global (OS)
Prazo: 5 anos
|
5 anos
|
|
|
Sobrevida livre de doença (DFS)
Prazo: 5 anos
|
5 anos
|
|
|
Reconstruction Module Pre- and Postoperative Scales BREAST-Q® Version 2.0
Prazo: 5 years
|
Score from 0 to 100, where 0 = the worst outcome and 100 = the best outcome
|
5 years
|
|
local, regional, and distant recurrence
Prazo: 5 years
|
5 years
|
|
|
reconstructive/aesthetic outcomes
Prazo: 1 year
|
Reconstructive outcomes: postoperative complications are classified as minor (Grade I-II : events requiring no intervention or managed with pharmacological treatment only) or major (Grade III-V: events requiring surgical, endoscopic, or radiological re-intervention). The primary reconstructive outcome measure is the proportion of patients experiencing at least one minor complication and at least one major complication at each time point, reported separately. Aesthetic outcomes and health-related quality of life are assessed using the BREAST-Q Reconstruction Module (version 2.0), a validated patient-reported outcome measure (PROM) specifically developed for breast reconstruction. The following domains are evaluated: satisfaction with breasts, satisfaction with overall outcome, psychosocial well-being, physical well-being (chest), and sexual well-being. Each domain is scored on a scale of 0-100 (higher scores indicating better outcomes), derived using the QScore algorithm. |
1 year
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- CE163/2026
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .